145 related articles for article (PubMed ID: 1780686)
1. Evaluation of TATI and other markers in solid tumors.
Taccone W; Mazzon W; Belli M
Scand J Clin Lab Invest Suppl; 1991; 207():25-32. PubMed ID: 1780686
[TBL] [Abstract][Full Text] [Related]
2. Tumor-associated trypsin inhibitor in pancreatic diseases.
Aroasio E; Piantino P
Scand J Clin Lab Invest Suppl; 1991; 207():71-3. PubMed ID: 1723534
[TBL] [Abstract][Full Text] [Related]
3. Tumor-associated trypsin inhibitor (TATI) in benign and malignant gastric disease.
Loizate Toricaguena A; Lamiquiz Vallejo A; Dominguez Merru-Urrutia MJ; Legorburu Escudero JF
Scand J Clin Lab Invest Suppl; 1991; 207():59-62. PubMed ID: 1780694
[TBL] [Abstract][Full Text] [Related]
4. Tumor-associated trypsin inhibitor (TATI) in patients with colorectal carcinoma. A critical comparison with CEA.
Catarino M; Conde R
Scand J Clin Lab Invest Suppl; 1991; 207():43-6. PubMed ID: 1780689
[TBL] [Abstract][Full Text] [Related]
5. The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients.
Fioretti P; Gadducci A; Ferdeghini M; Prontera C; Malagnino G; Facchini V; Mariani G; Bianchi R
Gynecol Oncol; 1992 Feb; 44(2):155-60. PubMed ID: 1544592
[TBL] [Abstract][Full Text] [Related]
6. Tumor-associated trypsin inhibitor, TATI, in gastrointestinal cancer and related benign diseases.
Piantino P; Arosaio E
Scand J Clin Lab Invest Suppl; 1991; 207():67-9. PubMed ID: 1780697
[TBL] [Abstract][Full Text] [Related]
7. Postoperative CEA is a better prognostic marker than CA19-9, hCGβ or TATI after resection of colorectal liver metastases.
Peltonen R; Österlund P; Lempinen M; Nordin A; Stenman UH; Isoniemi H
Tumour Biol; 2018 Jan; 40(1):1010428317752944. PubMed ID: 29378497
[TBL] [Abstract][Full Text] [Related]
8. TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder.
Pectasides D; Bafaloucos D; Antoniou F; Gogou L; Economides N; Varthalitis J; Dimitriades M; Kosmidis P; Athanassiou A
Am J Clin Oncol; 1996 Jun; 19(3):271-7. PubMed ID: 8638540
[TBL] [Abstract][Full Text] [Related]
9. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis.
Gadducci A; Ferdeghini M; Prontera C; Moretti L; Mariani G; Bianchi R; Fioretti P
Gynecol Oncol; 1992 Feb; 44(2):147-54. PubMed ID: 1312052
[TBL] [Abstract][Full Text] [Related]
10. TATI (tumour-associated trypsin inhibitor) as a marker of ovarian cancer.
Medl M; Ogris E; Peters-Engl C; Leodolter S
Br J Cancer; 1995 May; 71(5):1051-4. PubMed ID: 7734298
[TBL] [Abstract][Full Text] [Related]
11. Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242.
Pasanen P; Eskelinen M; Kulju A; Penttilä I; Janatuinen E; Alhava E
Scand J Clin Lab Invest; 1995 Apr; 55(2):119-24. PubMed ID: 7667604
[TBL] [Abstract][Full Text] [Related]
12. Tumour-associated trypsin inhibitor (TATI) in ovarian cancer.
Halila H; Lehtovirta P; Stenman UH
Br J Cancer; 1988 Mar; 57(3):304-7. PubMed ID: 3162682
[TBL] [Abstract][Full Text] [Related]
13. Comparison of tumor-associated trypsin inhibitor (TATI) with CA125 as a marker for diagnosis and monitoring of epithelial ovarian cancer.
Gadducci A; Ferdeghini M; Rispoli G; Prontera C; Bianchi R; Fioretti P
Scand J Clin Lab Invest Suppl; 1991; 207():19-24. PubMed ID: 1780685
[TBL] [Abstract][Full Text] [Related]
14. Tumor-associated trypsin inhibitor (TATI) in the diagnosis of lung cancer.
Pecchio F; Rapellino M; Baldi S; Casali V; Libertucci D; Coni F
Scand J Clin Lab Invest Suppl; 1991; 207():63-4. PubMed ID: 1780695
[TBL] [Abstract][Full Text] [Related]
15. Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer.
Peters-Engl C; Medl M; Ogris E; Leodolter S
Anticancer Res; 1995; 15(6B):2727-30. PubMed ID: 8669854
[TBL] [Abstract][Full Text] [Related]
16. Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patients.
Gaber A; Nodin B; Hotakainen K; Nilsson E; Stenman UH; Bjartell A; Birgisson H; Jirström K
BMC Cancer; 2010 Sep; 10():498. PubMed ID: 20849596
[TBL] [Abstract][Full Text] [Related]
17. Tumour-associated trypsin inhibitor and renal cell carcinoma.
Meria P; Toubert ME; Cussenot O; Bassi S; Janssen T; Desgrandchamps F; Cortesse A; Schlageter MH; Teillac P; Le Duc A
Eur Urol; 1995; 27(3):223-6. PubMed ID: 7601186
[TBL] [Abstract][Full Text] [Related]
18. Tumor-associated trypsin inhibitor (TATI) in primary esophageal carcinoma.
Gion M; Mione R; Tremolada C; Dalla Palma P; Ruol A; Dittadi R; Leon A; Nosadini A; Castoro C; Bruscagnin G
Scand J Clin Lab Invest Suppl; 1991; 207():37-41. PubMed ID: 1780688
[TBL] [Abstract][Full Text] [Related]
19. Tumor-associated trypsin inhibitor (TATI) in pleural effusions.
Rapellino M; Pecchio F; Baldi S; Adamo MR; Macri M; Ricardi G
Scand J Clin Lab Invest Suppl; 1991; 207():47-9. PubMed ID: 1780690
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of the tumour-associated trypsin inhibitor in patients with endometriosis.
Medl M; Ogris E; Peters-Engl C; Mierau M; Buxbaum P; Leodolter S
Br J Obstet Gynaecol; 1997 Jan; 104(1):78-81. PubMed ID: 8988701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
